Cardiovascular genetics testing just got a bigger market. Here is what commercial teams should do about it

Most commercial teams selling inherited cardiovascular risk spent the last five years fighting one objection. Some version of “interesting, but it is not in the guideline.” In March 2026 that objection stopped working. The American College of Cardiology and the American Heart Association released a new dyslipidemia guideline, the first full rewrite since 2018, and it moved inherited risk from a specialist interest to a standing recommendation for every adult in the country. If you carry a number in cardiovascular genetics testing, your commercial reality changed in one afternoon. Here is what changed, and what we would do with it if it were our territory.

What the guideline actually says

Four things matter commercially.

First, lipoprotein(a) should be measured at least once in every adult. That is a Class 1 recommendation, and it is the first time a United States guideline has called for universal measurement of an inherited risk marker. Not high risk adults. Not adults with a family history. All of them.

Second, children get screened. Universal lipid screening between ages nine and eleven if they have not been tested, and as early as age two when there is a family history of premature cardiovascular disease, severe hypercholesterolemia, or known familial hypercholesterolemia.

Third, genetic testing and cascade screening for familial hypercholesterolemia are called out directly. One diagnosed person is treated as a doorway to a family, not as a closed case.

Fourth, the treatment targets got harder. Below 55 milligrams per deciliter of LDL cholesterol at very high risk, 70 or lower at high risk, 100 for the lowest risk group. Harder targets mean more people who need something beyond a statin, which means more reason to know who is actually at risk.

Read what the guideline declined to endorse as well. Routine advanced lipoprotein testing for particle size is not recommended for risk estimation, and neither are supplements for lowering LDL cholesterol. If either is on your menu or in your pitch, that part of your story just lost its cover.

Why one sentence in a guideline moves more revenue than a landmark study

This is the part I wish more scientific founders understood. A strong publication gives your team a slide. A guideline recommendation gives your buyer permission.

Guidelines are what order sets get built from. They are what laboratory directors use to justify adding an assay to the menu, and what a medical director points at when finance asks why volume went up. When something moves from “emerging evidence” to a numbered recommendation, the conversation inside your customer changes from “should we believe this” to “how do we operationalize it.” Those are completely different sales cycles. The first one you lose slowly. The second one you can actually run a process against.

Now put the demand gap next to it. Roughly one in five people carry an elevated lipoprotein(a) level, and Family Heart Foundation research shows that fewer than five percent of Americans have ever been screened for it. A universal recommendation just landed on top of a market where almost nobody has been tested. That is not a slow build. That is a backlog.

The buyer moved, and most commercial teams have not

Here is the trap. If measurement is universal, the person ordering the test is no longer only the preventive cardiologist you have spent three years courting.

It is the primary care physician who now owns a new line in an annual visit. It is pediatrics, which just inherited a screening mandate. It is the health system laboratory director deciding whether to send it out or bring it in, and the population health leader who has to make the numbers work across thousands of attributed lives.

Those buyers do not speak the language your deck is written in. A preventive cardiologist wants to talk about risk reclassification and polygenic risk scoring. A primary care lead wants to know how many extra seconds it adds to a visit, who explains an abnormal result to the patient, and whether it will get paid. Same product, completely different first sentence.

Add one more tailwind. On July 16 of this year the FDA approved the first once daily oral option in the PCSK9 inhibitor class, with placebo adjusted LDL cholesterol reductions of 56 and 59 percent in its Phase 3 trials, which puts a pill in the same range as the injectables. Identifying inherited risk has always run into the same wall, which is a clinician asking what exactly they are supposed to do with the answer. An oral option makes that wall shorter. Testing companies benefit from treatment convenience even when they sell nothing on the therapy side.

Building a cardiovascular genetics testing commercial plan around this

Four moves, in the order I would run them.

Rewrite your opening line. Lead with what changed in the guideline, not with how your assay works. Your buyer already believes the science is real. What they need is a reason this is a 2026 problem instead of a someday problem, and the guideline is that reason, in one sentence, from a source they already trust.

Widen the call point list. If your target list is still cardiology only, you are working a fraction of the market the guideline just created. Build separate messaging tracks for primary care, pediatrics, laboratory operations, and population health, and staff them with people senior enough to hold the economic conversation, not just the clinical one.

Build the cascade motion deliberately. The guideline treats one positive familial hypercholesterolemia result as a signal to test the family. Commercially, that is expansion revenue sitting inside accounts you already won, and almost nobody has a defined play for it. Whoever builds that play first gets a compounding volume curve instead of a flat one.

Prune what the guideline did not support. Nothing burns credibility with a scientific buyer faster than pitching something they know was explicitly not recommended. Cut it, and use the space to talk about what was.

What we are seeing in the field

We run outreach into cardiology and diagnostics every day, so a quick check from our own data. Across roughly 9,900 decision makers our team has contacted on LinkedIn, personalized conversations run a reply rate just under 27 percent. The pattern in cardiovascular work is that messages opening on what changed for the clinician get answered, and messages opening on assay specifications get ignored. That is the difference between talking about their week and talking about your product.

The other thing we notice is timing. Guideline language takes twelve to thirty six months to reach order sets and standing panels. That lag is not a reason to wait. It is the window. The company that shapes how a health system thinks about implementing a recommendation is usually the company written into the workflow when implementation finally happens. Show up during the debate, not after it.

The honest summary

The science in this field was never the bottleneck. Adoption was. A guideline that tells every clinician in the country to measure an inherited risk marker at least once removes the biggest excuse your buyers had for doing nothing, and it does it across a market that is more than ninety five percent untested. That setup is rare, and it will not stay open forever. If you are carrying a cardiovascular genetics number this year and your outreach still sounds like it was written in 2024, that is the fix worth making this quarter.

We build and run outsourced commercial teams for diagnostic, biotech, and pharmaceutical brands across the United States and Canada, including the outreach, the senior selling, and showing up in person at the shows your buyers attend. Tell us what you’re selling and who you’re trying to reach. We’ll come back with a plan. Start here: https://www.northstarsci.com/contact